Changes in serum alpha fetoprotein in patients with recurrent hepatocellular carcinoma following hepatectomy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 9, 2015, Pages 1405-1411

  Liu, Guanghua ^a,b   Wang, Kui ^a   Li, Jun ^a   Xia, Yong ^a   Lu, Lihua ^a   Wan, Xuying ^a   Yan, Zhenlin ^a   Shi, Lehua ^a   Lau, Wan Yee ^a,c   Wu, Mengchao ^a   Shen, Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Alpha fetoprotein; Hepatectomy; Hepatocellular carcinoma; Recurrence

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; TUMOR INVASION; BLOOD; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE;

ADULT; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES;

EID: 84937890026     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12953     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011; 61: 69-90.
2. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004; 130: 417-422.
3. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009; 137: 110-118.
4. Johnson PJ. Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1999; 14 (Suppl.): S32-36.
5. Tangkijvanich P, Anukulkarnkusol N, Suwangool P etal. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J. Clin. Gastroenterol. 2000; 31: 302-308.
6. Trevisani F, D'Intino PE, Morselli-Labate AM etal. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol. 2001; 34: 570-575.
7. Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14: 717-725.
8. Memon K, Kulik L, Lewandowski RJ etal. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J. Hepatol. 2012; 56: 1112-1120.
9. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-66.
10. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62 (Suppl. 1): 57-63.
11. Matsuda M, Asakawa M, Amemiya H, Fujii H. Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC. J. Gastroenterol. Hepatol. 2011; 26: 731-738.
12. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann. Surg. 1999; 229: 216-222.
13. Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J. Natl. Cancer Inst. 1980; 64: 1329-1332.
14. Hsieh CB, Chen TW, Chu CM, Chu HC, Yu CP, Chung KP. Is inconsistency of alpha-fetoprotein level a good prognosticator for hepatocellular carcinoma recurrence? World J. Gastroenterol. 2010; 16: 3049-3055.
15. Wang K, Liu J, Yan ZL etal. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010; 52: 164-173.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
17. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer 1954; 7: 462-503.
18. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-338.
19. Vauthey JN, Lauwers GY, Esnaola NF etal. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 2002; 20: 1527-1536.
20. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 2001; 35: 421-430.
21. Sanai FM, Sobki S, Bzeizi KI etal. Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig. Dis. Sci. 2010; 55: 3568-3575.
22. Pateron D, Ganne N, Trinchet JC etal. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J. Hepatol. 1994; 20: 65-71.
23. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 2004; 112: 44-50.
24. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
25. Lin YJ, Lee MH, Yang HI etal. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS ONE 2013; 8: e61448.
26. Peng SY, Lai PL, Chu JS etal. Expression and hypomethylation of alpha-fetoprotein gene in unicentric and multicentric human hepatocellular carcinomas. Hepatology 1993; 17: 35-41.
27. Li P, Wang SS, Liu H etal. Elevated serum alpha fetoprotein levels promote pathological progression of hepatocellular carcinoma. World J. Gastroenterol. 2011; 17: 4563-4571.
28. Wang S, Jiang W, Chen X etal. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. J. Hepatol. 2012; 57: 322-329.
29. Morimoto O, Nagano H, Sakon M etal. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J. Hepatol. 2003; 39: 215-221.
30. Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 1999; 29: 1446-1452.
31. Taniguchi K, Yamada T, Sasaki Y, Kato K. Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma. BMC Cancer 2010; 10: 530.